- Home
- LVTX
as 10-28-2025 4:00pm EST
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.
| Founded: | 2016 | Country: | Netherlands |
| Employees: | N/A | City: | UTRECHT |
| Market Cap: | 40.0M | IPO Year: | 2021 |
| Target Price: | $1.58 | AVG Volume (30 days): | 513.1K |
| Analyst Decision: | Hold | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.05 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.85 - $2.06 | Next Earning Date: | 12-09-2025 |
| Revenue: | $4,990,000 | Revenue Growth: | -32.55% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of LAVA Therapeutics N.V. (LVTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Cooperatieve Gilde Healthcare IV U.A. | LVTX | 10% Owner | Oct 17 '25 | Sell | $1.47 | 1,181,131 | $1,736,262.57 | 2,947,781 | |
| Cooperatieve Gilde Healthcare IV U.A. | LVTX | 10% Owner | Oct 16 '25 | Sell | $1.49 | 690,239 | $1,028,456.11 | 2,947,781 | |
| Cooperatieve Gilde Healthcare IV U.A. | LVTX | 10% Owner | Oct 14 '25 | Sell | $1.51 | 227,341 | $343,284.91 | 2,947,781 | |
| Cooperatieve Gilde Healthcare IV U.A. | LVTX | 10% Owner | Oct 13 '25 | Sell | $1.54 | 47,686 | $73,436.44 | 2,947,781 | |
| Versant Venture Capital VI, L.P. | LVTX | 10% Owner | Sep 19 '25 | Sell | $1.40 | 2,903,403 | $4,068,828.96 | 0 | |
| Versant Venture Capital VI, L.P. | LVTX | 10% Owner | Sep 18 '25 | Sell | $1.44 | 594,902 | $857,729.70 | 0 | |
| Versant Venture Capital VI, L.P. | LVTX | 10% Owner | Sep 17 '25 | Sell | $1.49 | 589,532 | $877,931.05 | 0 | |
| Versant Venture Capital VI, L.P. | LVTX | 10% Owner | Sep 16 '25 | Sell | $1.53 | 500,000 | $766,600.00 | 0 |
Latest LAVA Therapeutics N.V. News
LVTX Breaking Stock News: Dive into LVTX Ticker-Specific Updates for Smart Investing
MT Newswires
12 days ago
XOMA Royalty Lowers Cash Offer for Lava Therapeutics, Extends Tender Deadline
GlobeNewswire
12 days ago
XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement
Simply Wall St.
5 months ago
Here's Why We're Watching LAVA Therapeutics' (NASDAQ:LVTX) Cash Burn Situation
GlobeNewswire
5 months ago
LAVA Reports First Quarter 2025 Financial Results, Provides Business Update
GlobeNewswire
6 months ago
LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation
GlobeNewswire
7 months ago
LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
GlobeNewswire
8 months ago
LAVA Announces Evaluation of Strategic Options
GlobeNewswire
10 months ago
LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers
Compare LVTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LVTX LAVA Therapeutics N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.